BMJ Open Safety of furazolidone-containing regimen in *Helicobacter pylori* infection: a systematic review and meta-analysis

Chao-ran Ji,^{1,2} Jing Liu,^{1,2} Yue-yue Li,^{1,2} Chuan-guo Guo,³ Jun-yan Qu,^{1,2} Yan Zhang,^{1,2} Xiuli Zuo ^{1,2}

To cite: Ji C, Liu J, Li Y, et al. Safety of furazolidone-containing regimen in *Helicobacter pylori* infection: a systematic review and meta-analysis. *BMJ Open* 2020;**10**:e037375. doi:10.1136/bmjopen-2020-037375

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-037375>).

Received 30 January 2020
Revised 07 August 2020
Accepted 22 August 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

²Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

³Department of Medicine, University of Hong Kong, Hong Kong, China

Correspondence to

Dr Xiuli Zuo;
zuoxiuli@sdu.edu.cn

ABSTRACT

Objectives Furazolidone containing regimen is effective for *Helicobacter pylori* (*H. pylori*) infection, but its safety remains controversial. To assess the safety of furazolidone containing regimen in *H. pylori* infection.

Design A systematic review and meta-analysis.

Data sources PubMed, Embase, Cochrane Library, Web of Science and Scopus databases were systematically searched for eligible randomised controlled trials.

Eligibility criteria Studies comparing furazolidone with non-furazolidone-containing regimen, variable durations or doses of furazolidone were included.

Data extraction and synthesis Two reviewers independently selected studies and extracted data. Primary outcomes were the risk of total adverse events (AEs), serious AEs and severe AEs, expressed as relative risk (RR) with 95% CI. Secondary outcomes contained the incidence of individual adverse symptoms, AE-related treatment discontinuation and compliance.

Results Twenty-six articles were identified from 2039 searched records, of which 14 studies (n=2540) compared furazolidone with other antibiotics. The eradication rates of furazolidone-containing regimen were higher than those of other antibiotics in both intention-to-treat (RR 1.06, 95% CI 1.01 to 1.12) and per-protocol analysis (RR 1.05, 95% CI 1.00 to 1.10). Only two serious AEs were reported in furazolidone group (2/1221, 0.16%). No significant increased risk was observed for the incidence of total AEs (RR 1.04, 95% CI 0.89 to 1.21) and severe AEs (RR 1.81, 95% CI 0.91 to 3.60). Twelve studies (n=3139) compared different durations of furazolidone, and four studies (n=343) assessed variable doses. Elevated risk of total AEs and severe AEs were only found in a high daily dose of furazolidone rather than prolonged duration. The incidence of AE-related treatment discontinuation and compliance of patients were all similar, irrespective of dose and duration adjustments.

Conclusion Furazolidone-containing regimen has a similar risk of AEs and compliance as non-furazolidone-containing regimen. A low daily dose of 200 mg is well-tolerated for 14 day regimen and should be first considered.

PROSPERO registration number CRD42019137247

INTRODUCTION

Helicobacter pylori infection affects up to 44.3% of the world's population.¹ Approximately

Strengths and limitations of this study

- This review screens trials in both initial and rescue treatment for *Helicobacter pylori* infection, so that there is a considerable amount of evidence to assess the safety of furazolidone-containing regimen.
- Effects of duration and dose on the safety of furazolidone are also analysed.
- The reporting of this review strictly follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. For the main results, sample size is measured by trial sequential analysis, and quality of evidence is graded according to the GRADE (grading of recommendations assessment, development and evaluation) approach.
- Limitations include most studies being open-labelled and lack of data from developed countries, which restricts the generalisability of study findings.

89% cases of non-cardia gastric cancer, which accounts for 78% gastric cancers, are attributed to *H. pylori*.^{2,3} Early detection and eradication of *H. pylori* can prevent the progression of gastric atrophy and reduce relative risks (RRs) for developing gastric cancers.^{4,5}

Facing the yearly increasing antibiotic resistance of *H. pylori* worldwide,⁶ traditional antibiotic-containing therapy is no longer reliable to achieve satisfying eradication rate.⁷ Additionally, failure of first-line therapy exacerbates the difficulty for rescue treatment with significantly increased clarithromycin and metronidazole resistance.⁸ Therefore, it's imperative to introduce new antibiotics with low drug resistance for the current regimen. As resistance of *H. pylori* to furazolidone remains below 5% in Asia and South America,⁹ it may be a key component in treatment success, especially in regions with high antibiotic resistance.

Furazolidone is a synthetic nitrofurantoin derivative with a broad antibacterial and antiprotozoal spectrum to treat gastrointestinal

tract infections.¹⁰ It's well-absorbed by oral administration, and was first used to treat *H. pylori* infection in 1985.¹¹ Few genetic mutations have been identified in *H. pylori* for its resistance, and rare cross-resistance was observed between furazolidone and other antibiotics,^{10 12 13} indicating it could be a good candidate for *H. pylori* eradication. However, the availability of furazolidone was restricted in developed countries for potential genotoxic and carcinogenic effects in animal experiments,^{14–16} but further research failed to provide any fundamental clinical evidence neither from case reports nor epidemiological studies.

Meanwhile, it's still available and widely used in developing countries owing to its good cost-effectiveness. Plenty of randomised controlled trials (RCTs) have confirmed the high efficacy of furazolidone in both initial and rescue treatment.¹⁷ A recent meta-analysis showed furazolidone was more effective than other antibiotics in the first-line quadruple therapy, with a pooled eradication rate exceeding 90% for per-protocol analysis. But up to now, there is still no definite answer to the safety of furazolidone in *H. pylori* eradication.

Herein, we systematically reviewed relevant RCTs up to date to assess the safety and compliance of furazolidone versus other antibiotic containing regimen for *H. pylori* eradication, and further evaluated its safety in variable durations and dose schemes.

METHOD

This meta-analysis was reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement,¹⁸ and registered on PROSPERO (international prospective register of systematic reviews) with the number: CRD42019137247.

Search strategy

Systematic literature search was conducted in PubMed, Embase, Cochrane Library, Web of Science and Scopus databases from inception to June 2019. A combination of MeSH and free terms was used to identify relevant clinical trials, including Furazolidone (with variations: Nifurazolidone, Furoxone or Furazol) and *Helicobacter* (with variations: *Helicobacter pylori* and *Campylobacter pylori*), with filters of RCTs applied to all the searching results (online supplemental appendix A). Clinicaltrials.gov, GreyNet, BIOSIS Previews, OCLC FirstSearch databases were also searched for unpublished trials and consensus reports with the same strategy. Then, we emailed authors to verify the results of retrieved studies, and manually checked reference lists of reviews, letters and included articles to identify any other relevant studies.

Inclusion and exclusion criteria

Only RCTs published in English or Chinese were eligible. The inclusion criteria were as follows: (1) *H. pylori* infection was confirmed by at least one standard detection method, including urea breath test, rapid urease test,

histology, culture or faecal antigen testing. (2) Studies included at least two arms of treatments comparing furazolidone with non-furazolidone-containing regimen, different treatment durations or various doses of furazolidone. (3) Studies compared furazolidone-containing therapy with placebo or proton pump inhibitor were also included. (4) Incidence of total adverse events (AEs) and serious AEs should be monitored and available for each study arm. Exclusion criteria included: (1) Studies that enrolled paediatric patients or patients with specific underlying disease. (2) Studies that used a daily dose of furazolidone over 400 mg (the highest recommended daily dose for adults). (3) Studies that compared different forms of furazolidone regimens (eg, quadruple versus triple therapy). (4) Studies that changed the dose, duration of drugs other than furazolidone or assessed additional interventions. (5) Studies with treatment duration less than 5 days or over 14 days. (6) Studies with incomplete safety data after contacting authors, including a blurry description of safety outcomes, failing to provide a separate incidence of total AEs for each study arm and lack of serious AEs recording.

Study selection

After removal of duplicates, two reviewers independently screened all the abstracts following the selection criteria to identify relevant studies. When a decision could not be made solely based on the abstract, full text was further reviewed to assess the inclusion. Any discrepancies between the two reviewers were resolved by discussion with a third reviewer.

Data extraction

Two reviewers separately used a standardised, electronic data collection form to extract all the relevant data from included studies. Primary outcomes were the incidence of total AEs and serious AEs. We adopted a definition of serious AEs from the International Council for Harmonisation (ICH) harmonised tripartite guideline E2A.¹⁹ Serious AEs were defined as life-threatening events requiring hospitalisation or prolonged existing hospitalisation, or resulting in persistent disability and even death. When available, the severity of AEs was also extracted. Severe AEs were defined as significant limitations to daily activity and sometimes even led to drug withdrawal.²⁰ Secondary outcomes were the incidence of individual adverse symptoms, the incidence of AE-related treatment discontinuation and compliance. Types of individual adverse symptoms were defined by preferred terms from the Medical Dictionary for Regulatory Activities V.19.0.²¹ The list of preferred terms included: gastrointestinal disorders (nausea, vomiting, diarrhoea, constipation, dyspepsia, abdominal pain, abdominal discomfort and flatulence), nervous system disorders (dizziness, somnolence, dysgeusia and headache), skin and subcutaneous tissue disorders (rash and pruritus), psychiatric disorders (anorexia and insomnia), general disorders (fatigue, fever and chills) and other specific symptoms. For analysis of

compliance, only patients taking at least one dose of drug were included, and the acceptable compliance level was defined as >80% for general acknowledgement. Besides, additional drug interventions, collecting methods of AEs, dose and duration of regimens were extracted for further analysis. Demographic characteristics such as age, country and baseline disease status were also extracted. Any observed data differences between the two collecting forms were checked against original texts and then examined by another reviewer to minimise human errors.

Risk of bias assessment

Two reviewers independently evaluated the methodological quality of RCTs using the first version of Cochrane Collaboration Risk of Bias tool²² with RevMan software V.5.3.5 (Nordic Cochrane Centre, Copenhagen, Denmark, 2014). When differences could not be solved by group discussions, a third reviewer was invited to make the final decision.

Data synthesis, analysis and grading of evidence

Meta-analysis was conducted using R software V.3.6.0 (R Foundation for Statistical Computing, Vienna, Austria, 2019). For pooled estimates of dichotomous outcomes, RR and 95% CI were calculated and synthesised by the Mantel-Haenszel approach. Significant *p* value was set at 0.05. Random effects model was preferentially applied for conservative evaluation of treatment effect size across studies. Statistical heterogeneity was assessed using both the *Q* test and *I*² statistic. A *p* value <0.1 for the *Q* test or *I*² value >50% indicated significant heterogeneity.²³ Then, subgroup analysis would be done to identify the possible causes. Subgroup categories included dose of furazolidone, quadruple or triple forms of regimens, country of patients, prompted collection (collecting AEs with active return visit call or interview) or passive collection of AEs (collecting AEs with written questionnaires or report cards). Risk of publication bias was assessed by funnel plots and quantified by the Egger's linear regression test²⁴ and the Begg's rank correlation test.²⁵ Trim and fill method was applied to revise existing publication bias.²⁶ Sensitivity analysis was performed by continuously excluding every single study in the pooled estimate, and recalculating the RR with remaining studies. The synthesised result would be considered unreliable if any obvious alterations occurred after exclusion.

For the incidence of total AEs between furazolidone and non-furazolidone-containing regimen, trial sequential analysis (TSA) was conducted to estimate the required information size using TSA viewer software V.0.9.5.10 (Copenhagen trial unit, Copenhagen, Denmark, 2016).^{27–28} Besides, two investigators independently graded the quality of evidence at outcome level, following

the grading of recommendations assessment, development and evaluation (GRADE) approach.²⁹

RESULTS

Search results and study characteristics

As shown in figure 1, a total of 2039 records were identified, of which 100 records were further assessed for eligibility. Finally, 26 articles met the selection criteria, enrolled in the meta-analysis and were further classified into three groups for different study aims. The consistency of study selection was good between two reviewers (κ statistic=0.83). Four of 26 articles involved two comparisons. Data from these articles were separately analysed and relevant sources were listed as a single study in each comparison group.

Fourteen studies compared furazolidone with non-furazolidone-containing regimen. The pooled intention-to-treat eradication rate was significantly higher in furazolidone containing ones (RR 1.06, 95% CI 1.01 to 1.12, online supplemental figure S1a). Similar superiority was also found in the per-protocol analysis (RR 1.05, 95% CI 1.00 to 1.10, online supplemental figure S1b). Twelve studies³⁰ evaluated the safety of furazolidone with different treatment durations, and four studies assessed variable doses. Prolonged duration to 14 days and higher daily dose significantly elevated the treatment efficacy (RR 1.05, 95% CI 1.02 to 1.08; RR 1.23, 95% CI 1.07 to 1.43). The main characteristics of above studies are summarised in table 1.

Risk of bias across the studies

Five studies were open-labelled trials, leading to high risk for performance bias. Twenty-one studies³⁰ used return visits or telephone interviews to promptly collect AEs without blinding to treatment allocation, which caused a high risk in detection bias. One study partially reported moderate and severe AEs, resulting in a high risk in reporting bias. Other biases were low or unclear in most studies (online supplemental figure S2).

Furazolidone versus non-furazolidone containing regimen

Overall safety outcomes

Fourteen studies involving 2540 patients showed furazolidone group and non-furazolidone group had a similar risk of total AEs (RR 1.04, 95% CI 0.89 to 1.21, figure 2A), with a pooled incidence rate of 19.33% (236/1,221) and 17.59% (232/1,319), respectively. Subgroup analysis by dose, duration and quadruple or triple forms of regimens also found no significant difference. Only two serious AEs were reported in furazolidone group (0.16%, 2/1,221). Both the patients received furazolidone and amoxicillin quadruple therapy, and were hospitalised for suspicion of allergy. No serious AEs were reported in non-furazolidone group. Five studies reported the incidence of severe AEs. The pooled incidence rates in the two groups were 5.82% (22/378) and 2.74% (10/365), with no significant

Figure 1 Flow chart for study selection. PPI, proton pump inhibitor.

increased risk detected (RR 1.81, 95% CI 0.91 to 3.60, [figure 2B](#)).

TSA analysis was performed for the incidence of total AEs between the two groups. Although the pooled population did not reach the estimated sample size, cumulative Z curve surpassed the inner futility line, indicating no significant difference would be detected even with an increased number of patients (online supplemental figure S3).

Individual adverse symptoms and compliance

Twelve studies provided detailed individual adverse symptoms, of which nausea and dizziness were commonly reported with a pooled incidence of 7.72%

(74/958) vs 9.18% (90/980), 6.95% (56/806) vs 6.29% (52/827), respectively. No significant differences were found ([table 2](#)) similarly for the results of abdominal pain, diarrhoea, vomiting, headache, fever, skin rash and anorexia.

Subgroup analysis by passive reports collection even found a lower RR of nausea in furazolidone group (RR 0.42, 95% CI 0.22 to 0.79, online supplemental figure S4). However, nine studies found a higher risk of dysgeusia in non-furazolidone group (RR 0.57, 95% CI 0.35 to 0.93, [table 2](#)).

Incidence of AE-related treatment discontinuation was similar in furazolidone (3.22% (19/590)) versus non-furazolidone group (2.25% (13/577)), with a RR of 1.30

Table 1 Main characteristics of involved studies

Study, year	Country	Mean age	Indications	Furazolidone regimen	Furazolidone dose	Duration	Incidence of total AEs	Control regimen	Incidence of total AEs
Characteristics of studies compared furazolidone with non-furazolidone containing regimen									
Liu <i>et al</i> , 1999 ⁵¹	China	44	NUD, PU	OCF	100 mg two times per day	7 days	20.00%, 7/35	OCM	22.86%, 8/35
Xiao <i>et al</i> , 1999 ⁵²	China	44	NUD, PU	BCF	100 mg two times per day	7 days	11.67%, 7/60	BCA	5.00%, 3/60
Malekzadeh <i>et al</i> , 2000	Iran	40	PU	R ¹ BAF	200 mg two times per day	14 days	26.00%, 13/50	R ¹ BAM	9.62%, 5/52
Fakheri <i>et al</i> , 2001	Iran	43	NUD, PU	OBAF	200 mg two times per day	14 days	63.49%, 40/63	OBAC	58.18%, 32/55
Xiao <i>et al</i> , 2001 ⁵³	China	44	PU	OCF	100 mg two times per day	7 days	20.09%, 46/229	OCM	20.09%, 44/219
Guo <i>et al</i> , 2004 ⁵⁴	China	40	NUD, PU	OAF	100 mg two times per day	7 days	15.63%, 5/32	OAC	22.58%, 7/31
				OCF	100 mg two times per day	7 days	18.18%, 6/33	OCM	29.03%, 9/31
Zhang <i>et al</i> , 2011 ⁵⁵	China	43	NUD, PU	OAF	100 mg two times per day	7 to 14 days	6.45%, 6/93	OAC	6.42%, 7/109
Zhang <i>et al</i> , 2012 ⁵⁶	China	47	Not specified	ECF	100 mg three times per day	7 days	20.45%, 9/44	ECA	13.33%, 6/45
								EC L ¹	18.18%, 8/44
Chen <i>et al</i> , 2013 ⁵⁷	China	41	NUD, PU	EBAF	100 mg two times per day	7 days	13.33%, 6/45	EBAC	10.42%, 5/48
Li <i>et al</i> , 2013 ⁵⁸	China	42	NUD, PU	RACF	200 mg two times per day	7 days	6.67%, 2/30	RACB/Bi	3.33%, 2/60
				RACF	200 mg two times per day	14 days	13.33%, 4/30	RACB/Bi	8.33%, 5/60
Liang <i>et al</i> , 2013 ⁵⁹	China	50	NUD, PU, GC	LBAF	100 mg three times per day	14 days	19.23%, 20/104	LBAT	16.19%, 17/105
				LBTF	100 mg three times per day	14 days	17.59%, 19/108	LBTM	33.64%, 36/107
Zheng <i>et al</i> , 2013 ⁶⁰	China	38	NUD, PU	EBAF	100 mg two times per day	10 days	11.25%, 9/80	EBAL ¹	9.21%, 7/76
Ke and Lu, 2018 ⁶¹	China	46	NUD, PU, GC	RBAF	100 mg two times per day	14 days	31.11%, 14/45	RBAC	30.23%, 13/43
				RBAF+Bi	100 mg two times per day	14 days	10.42%, 5/48	RBAC+Bi	10.87%, 5/46
Yi <i>et al</i> , 2019 ⁶²	China	44	NUD, PU	EBAF	100 mg two times per day	14 days	19.57%, 18/92	EBAC	13.98%, 13/93
Characteristics of studies compared long duration versus short duration of furazolidone									
Wang <i>et al</i> , 2004 ⁶³	China	43	NUD, PU	RCF	7 days	38.00%, 19/50	RCF	5 days	8.89%, 4/45
Daghaghzadeh <i>et al</i> , 2007 ⁶⁴	Iran	45	NUD, PU	OBAF	14 days	38.46%, 30/78	OBAF	7 days	24.36%, 19/78

Continued

Table 1 Continued

Study, year	Country	Mean age	Indications	Furazolidone regimen	Furazolidone dose	Duration	Incidence of total AEs	Control regimen	Incidence of total AEs
Cheng and Hu, 2009 ⁶⁵	China	50	NUD, PU	RBAF	14 days	15.00%, 3/20	RBAF	7 days	10.00%, 2/20
Zhang <i>et al</i> , 2011 ⁶⁶	China	43	NUD	OAF	10 or 14 days	7.94%, 5/63	OAF	7 days	3.33%, 1/30
				OL ¹ F	10 or 14 days	11.67%, 7/60	OL ¹ F	7 days	6.67%, 2/30
Zhao and Huo, 2012 ⁶⁶	China	46	NUD, PU	EAF	10 days	4.17%, 2/48	EAF	7 days	4.17%, 2/48
				EBAF	10 days	4.08%, 2/49	EBAF	7 days	6.38%, 3/47
Chen <i>et al</i> , 2013 ⁶⁷	China	42	NUD, PU	EBAF	10 days	6.38%, 3/47	EBAF	7 days	13.33%, 6/45
Li <i>et al</i> , 2013 ⁶⁸	China	44	NUD, PU	RACF	14 days	13.33%, 4/30	RACF	7 days	6.67%, 2/30
Zheng <i>et al</i> , 2013 ⁶⁹	China	50	NUD, PU	EBAF	14 days	16.67%, 10/60	EBAF	10 days	11.86%, 7/59
Xie <i>et al</i> , 2014 ⁶⁷	China	41	PU	RAF	10 days	8.33%, 15/180	RAF	7 days	8.33%, 15/180
Mokhtare <i>et al</i> *, 2015 ⁶⁸	Iran	44	Not specified	OBAF	10 days	9.44%, 17/180	RBAF	7 days	8.89%, 16/180
						38.71%, 48/124	OBAM-F	5 days	29.03%, 36/124
Xu <i>et al</i> , 2015 ⁶⁹	China	44	NUD, PU	PBAF	10 days	1.67%, 2/120	PBAF	7 days	1.67%, 2/120
				PAF	10 days	1.67%, 2/120	PAF	7 days	0.83%, 1/120
Xie <i>et al</i> , 2018 ⁷⁰	China	44	Not specified	EBAF	10 days	9.68%, 18/186	EBAF	7 days	7.41%, 14/189
				EAF	10 days	8.02%, 15/187	EAF	7 days	7.29%, 14/192
Characteristics of studies compared high dose versus low dose of furazolidone									
Coelho <i>et al</i> , 2003 ⁷¹	Brazil	43	NUD	LCF	7 days	400 mg two times per day	17.50%, 7/40	200 mg once per day	17.95%, 7/39
Roghani <i>et al</i> , 2003 ⁷²	Iran	38	PU	OAF	14 days	200 mg two times per day	90.48%, 57/63	50 mg two times per day	16.39%, 10/61
Fakheri <i>et al</i> , 2004 ⁷³	Iran	46	PU	OABF	14 days	200 mg two times per day	62.00%, 31/50	100 mg two times per day	10.00%, 5/50
Cheng and Hu, 2009 ⁶⁵	China	48	NUD, PU	RBAF	14 days	100 mg three times per day	30.00%, 6/20	100 mg two times per day	15.00%, 3/20

*Mokhtare *et al* was the only one study using sequential regimen. The number in the short duration column refers to the treatment length of furazolidone.

A, amoxicillin; AE, adverse events; B, bismuth; B/Bi, using bismuth or bifidobacterium in the same regimen; Bi, bifidobacterium; C, clarithromycin; E, esomeprazole; F, furazolidone; GC, gastric cancer; L¹, levofloxacin; L, lansoprazole; M, metronidazole; M-F, Metronidazole for the first 5 days followed by furazolidone for the second 5 days; NUD, non-ulcer dyspepsia; O, omeprazole; P, pantoprazole; PU, peptic ulcer; R¹, ranitidine; R, rabeprazole; T, tetracycline.

Figure 2 Furazolidone versus non-furazolidone-containing regimen: (a) Incidence of total adverse events. (b) Incidence of severe adverse events. RR, relative risk.

(95% CI 0.65 to 2.63, table 2). Patients' compliance was almost the same between two groups. (96.94% vs 96.67%, RR 1.00, 95% CI 0.99 to 1.01, table 2). Low heterogeneities were detected in these analysis.

Long duration versus short duration of furazolidone

Overall safety outcomes

Twelve studies involving 3139 patients found a higher risk of total AEs in the long-duration group (RR 1.33, 95% CI 1.09 to 1.61), which was dose-related and became non-significant with a daily dose of 200 mg (RR 1.27, 95% CI 0.92 to 1.76, figure 3). The majority of AEs were still well-tolerated, no serious AEs occurred in either group and no increased risk of severe AEs was observed (RR 1.04, 95% CI 0.38 to 2.86, table 2).

Individual adverse symptoms and compliance

Nine studies were included for analysis of individual adverse symptoms.³⁰ No increased risk was observed for nausea, dizziness, vomiting, diarrhoea or fatigue. Risk of AE-related treatment discontinuation and patients' compliance were also similar between the two groups. The heterogeneities were low for the above comparisons (table 2).

High dose versus low dose of furazolidone

Overall safety outcomes

Four studies with a total of 343 patients found an increased risk of total AEs in high daily dose of furazolidone (RR 3.04, 95% CI 1.28 to 7.22, figure 4A). Subgroup analysis showed similar result in a 14-day regimen with low heterogeneity (RR 4.87, 95% CI 2.89 to 8.18, figure 4A). Similarly, an elevated risk of severe AEs was observed in high-dose group (RR 3.74, 95% CI 1.29 to 10.86, figure 4B), but none of them was classified as serious AEs among all the involved patients.

Individual adverse symptoms and compliance

Data from three studies showed an obvious increased risk of nausea and dizziness in high dose versus low dose of furazolidone (RR 4.63, 95% CI 1.49 to 14.40; RR 12.28, 95% CI 2.95 to 51.07, respectively, table 2), but risk was similar for diarrhoea and headache. For analysis of compliance, a high heterogeneity arose from Roghani *et al*, 2003, which used a four-fold dose of furazolidone in the high-dose group compared with control. Subgroup analysis showed compliance was not compromised in a higher dose regimen. Risk of treatment discontinuation was also similar regardless of dosage change (table 2).

Grading of evidence

All the involved RCTs had serious study limitations for lack of allocation concealments or blinding to the treatment arms. Accordingly, the certainty of evidence was downgraded to a moderate level for most conclusions. In high dose versus low dose of furazolidone, the quality of evidence was rated low for a wide CI (table 2).

Publication bias

No publication bias were detected by the Egger's and Begg's test for the main outcomes (table 2).

Sensitivity analysis

For incidence of dysgeusia between furazolidone and non-furazolidone-containing regimen, the pooled estimates obviously shifted to a no significant level after excluding Fakheri *et al*, 2001 (online supplemental figure S5). For analysis between variable doses of furazolidone, the synthetic results were unstable for incidence of total AEs, severe AEs and nausea. But incidence of total AEs and nausea became robust to sensitivity analysis after additionally included Hosseini *et al*,³¹ 2014, which compared a daily dose of furazolidone in 600 mg versus 400 mg (online supplemental figure S6).

DISCUSSION

In this meta-analysis, data of 2540 patients from 14 RCTs showed that furazolidone-containing regimen had no increased risks of total AEs or severe AEs, while maintaining higher efficacy compared with non-furazolidone-containing regimen. Only two serious AEs were reported in furazolidone group. The majority of AEs were well-tolerated with a low incidence of discontinuation and excellent compliance (>95%) to the treatment.³²

Compared with other antibiotic regimens, furazolidone-containing regimen had superior efficacy with a similar risk of total AEs, irrespective of altered daily dose, duration and regimen forms. These results were consistent with findings in a recent meta-analysis, in which no increased risks of total AEs and severe AEs were found in seven RCTs comparing furazolidone with other antibiotic-containing regimens. The RR was 1.01 (95%CI 0.91 to 1.11) for total AEs and 1.70 (95%CI 0.84 to 3.47) for severe AEs. But these results were partially collected for

Table 2 Summary of primary and secondary outcomes

Analyses	No. of studies	No. of patients	RR (95% CI)	I ² %	P value for heterogeneity	P value for Egger's test	P value for Begg's test	Quality of evidence (GRADE)
Furazolidone versus non-furazolidone-containing regimen								
Incidence of total AEs	14	2540	1.04 (0.89 to 1.21)	0	0.45	0.09	0.07	Moderate*
Incidence of severe AEs	5	743	1.81 (0.91 to 3.60)	0	0.91	–	–	Moderate*
Incidence of discontinuation	6	1167	1.30 (0.65 to 2.63)	0	0.80	–	–	Moderate*
Compliance	13	2373	1.00 (0.99 to 1.01)	0	0.90	0.88	0.71	Moderate*
Incidence of nausea	10	1938	0.88 (0.55 to 1.43)	52	0.03	0.39	0.93	–
Incidence of dizziness	8	1633	1.09 (0.76 to 1.57)	1	0.42	–	–	–
Incidence of dysgeusia	9	1488	0.57 (0.35 to 0.93)	15	0.31	–	–	–
Long duration versus short duration of furazolidone-containing regimen								
Incidence of total AEs	12	3139	1.33 (1.09 to 1.61)	0	0.48	0.73	0.89	Moderate*
Incidence of severe AEs	4	1003	1.04 (0.38 to 2.86)	0	0.72	–	–	–
Incidence of discontinuation	6	2477	1.22 (0.73 to 2.02)	0	0.96	–	–	–
Compliance	11	2971	1.00 (0.98 to 1.01)	0	0.48	0.89	0.82	–
High dose versus low dose of furazolidone-containing regimen								
Incidence of total AEs	4	343	3.04 (1.28 to 7.22)	75	<0.01	–	–	Low*† ⁷⁴
Incidence of severe AEs	3	303	3.74 (1.29 to 10.86)	0	0.82	–	–	–
Incidence of discontinuation	2	224	5.37 (0.63 to 45.71)	0	0.62	–	–	–
Compliance	4	343	0.99 (0.93 to 1.06)	69	0.02	–	–	–
Incidence of nausea	3	264	4.63 (1.49 to 14.40)	0	0.69	–	–	–
Incidence of dizziness	3	264	12.28 (2.95 to 51.07)	0	0.79	–	–	–

*Downgraded by the open-label design of enrolled studies.

†Downgraded by the wide CI.

AE, adverse events; GRADE, grading of recommendations assessment, development and evaluation ; RR, relative risk.

Figure 3 Long duration versus short duration of furazolidone for incidence of total adverse events.

patients with naïve infection. We additionally included patients receiving rescue treatments, designed a research strategy specialised for safety outcomes and further verified these findings. However, the quality of evidence was moderate, as most RCTs were poorly designed without allocation concealment and blinding method.

For analysis of individual adverse symptoms, no increased risks of nausea, vomiting, abdominal pain, diarrhoea, headache, fever, skin rash or anorexia were detected in patients receiving furazolidone. While, patients receiving other antibiotics were easy to have dysgeusia, which was probably caused by the wide clarithromycin use in 11 of 14 studies. But these results should be taken seriously, as sensitivity analysis detected significant alterations in the pooled estimates after excluding certain study. More evidence is required to draw a confirmed conclusion.

Additionally, we assessed the safety outcomes in variable duration and dose of furazolidone. Among patients who received a daily dose of 200 mg, no increased risk of total AEs was detected even with extended treatment duration to 14 days. When given a high daily dose of furazolidone

Figure 4 High dose versus low dose of furazolidone: (a) Incidence of total adverse events. (b) Incidence of severe adverse events. RR, relative risk.

ranging from 300 mg to 400mg, patients had an obvious higher risk of total AEs and severe AEs compared with the low-dose regimen. Meanwhile, the incidence of nausea and dizziness also became more frequent, which was similar with results reported by Zhuge *et al.*³³ These findings suggested that prescription of furazolidone should be started with a minimum necessary dose of 100 mg twice daily to avoid potential severe AEs. If a low-dose regimen fails to achieve expected therapeutic efficacy, extending the duration of furazolidone should be first considered rather than increasing the daily dose.

Concerns over furazolidone related irreversible AEs restricted its availability in developed countries, but up to now, no supporting clinical evidence has been reported. The International Agency for Research on Cancer (IARC) classified furazolidone as a category 3 agent with unclassifiable carcinogenicity, while metronidazole was classified as a category 2B agent with possible carcinogenicity to humans.³⁴ Some researchers pointed out there might be some misunderstanding of furazolidone.³⁵ Currently, the recommended *H. pylori* eradication schedules were 10 to 14 days. Considering the resistance to furazolidone is still rare worldwide, the benefits of short-term clinical use could easily outweigh the possible but low risk.

China has a long history use of furazolidone to cure ulcers even before the discovery of *H. pylori*. Our results showed that among 4505 patients receiving furazolidone-containing regimen in 26 trials, only two cases of serious AEs were reported with a rare incidence rate of 0.04%, which indicated the adverse reactions of furazolidone might be exaggerated in previous reviews. Both the patients received furazolidone and amoxicillin quadruple therapy, and were hospitalised for severe skin rash, flushing and abdominal colic. As allergy to penicillin is commonly reported in 10% of the population, hypersensitivity reactions to amoxicillin could not be ruled out.³⁶ Three patients reported numbness of limbs with suspicion of peripheral neuritis, but symptoms relieved spontaneously after stopping treatment and supplements of vitamin B1 and B6. Other severe adverse symptoms mostly disappeared after drug withdrawal without additional treatments (online supplemental table S1).

The occasionally occurring severe AEs were most likely related to the monoamine oxidase inhibitory properties of furazolidone.³⁷ One of its major metabolite, amino-2-oxazolidone, can non-selectively inhibit the monoamine oxidase activity, interact with metabolism of tyramine and cause dose-dependent gastrointestinal and nervous system disorders.³⁸ Notably, two specific AEs were reported in previous studies. One was disulfiram-like reaction to alcohol and the other was haemolytic anaemia in glucose-6-phosphate dehydrogenase (G-6-PD) deficient patients.³⁹ Thus, it should not be given concurrently to individuals already taking other monoamine oxidase inhibitors or antidepressants, or having decreased G-6-PD activity. Alcohol should also be avoided when furazolidone is being used.

Apart from the combination with antacids for *H. pylori* eradication, furazolidone was widely used alone for the treatment of traveller's diarrhoea, typhoid fever, cholera and *salmonella* infections. The most commonly reported AEs were gastrointestinal distress, dizziness, somnolence, headaches and general malaise.⁴⁰ In a review that quantified 191 studies, the frequency of AEs to furazolidone was 8.3% (864/10 443) in gastrointestinal infections. Most adverse symptoms were mild, with an incidence below 1%, and no drug-induced death recorded. One RCT compared furazolidone (100 mg once a day for 5 days) with ampicillin among 94 patients with traveller's diarrhoea. Only one patient receiving furazolidone dropped out due to local skin rash.⁴¹ Another RCT assessed different doses of furazolidone in 57 children with cholera. No drug-related discontinuation of treatment occurred.⁴² These data further confirm the safety of furazolidone as a single agent in treating a infectious disease.

We first evaluated the safety of furazolidone-containing regimen as a primary outcome and pointed out the increased risk of AEs was mainly attributed to the high daily dose of furazolidone. In previous meta-analyses,^{43–44} safety of furazolidone regimen was only assessed as a secondary outcome, and relevant data was partially collected from RCTs eligible for efficacy analysis. Under this condition, selection bias was inevitable for incomplete data retrieval. To overcome these drawbacks, we first developed a search strategy specialised for safety evaluation, additionally included both initial and rescue treatments, and updated search scopes from 2016 to June 2019. Besides, we analysed the safety of furazolidone in variable doses and durations schemes, and first concluded a daily dose of 200 mg is safe for current 14-day eradication regimen.

This meta-analysis did have several limitations. First, most included studies did not mention allocation concealment and blinding method in the study design, which led to high detection bias of AEs reporting. Therefore, more high-quality evidence from double-blind RCTs is warranted to assess the safety outcomes accurately. Second, as the completion of treatment was around 6 to 8 weeks, incidence of delayed adverse reactions cannot be evaluated with limited follow-up duration. Finally, current conclusions are mainly based on clinical data from Asian people and developing countries. Available safety data in Western people are all from small pilot studies, and no serious AEs was observed.^{45–50} More large-scale clinical trials are needed to assess the effectiveness and safety of furazolidone-containing regimen in developed countries.

In conclusion, furazolidone has similar risk of AEs as non-furazolidone-containing regimens, while maintaining good efficacy and high compliance. The majority of AEs are mild-to-moderate with a low occurrence of treatment discontinuation and excellent compliance of patients, which is not compromised by increased dose and duration of furazolidone. Higher incidence

of total AEs and severe AEs for furazolidone are mainly attributed to increased dose rather than prolonged duration. A low daily dose of 200 mg is safe and well-tolerated for 14-day regimen, which should be recommended for *H. pylori* infection.

Acknowledgements We are grateful to Rui Zhao and Qing-fang Zhang for providing the original data to support our research.

Collaborators Not applied.

Contributors XZ and CJ designed the study and wrote the manuscript. CJ, JL and YL collected the data and evaluated the quality of evidence. CJ analysed the data. CG, JQ and YZ helped with data interpretation and gave a critical review of the manuscript. All the authors have approved the final version of the manuscript.

Funding This research was supported by the National Natural Science Foundation of China (81 770 538 and 81570485), the Key Research and Development Program of Shandong Province (2017CXGC1215).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer-reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Xiuli Zuo <http://orcid.org/0000-0001-9556-8771>

REFERENCES

- 1 Zamani M, Ebrahimitabar F, Zamani V, *et al*. Systematic review with meta-analysis: the worldwide prevalence of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2018;47:868–76.
- 2 Peek RM, Blaser MJ. *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nat Rev Cancer* 2002;2:28–37.
- 3 Plummer M, Franceschi S, Vignat J, *et al*. Global burden of gastric cancer attributable to *Helicobacter pylori*. *Int J Cancer* 2015;136:487–90.
- 4 Ford AC, Forman D, Hunt R, *et al*. *Helicobacter pylori* eradication for the prevention of gastric neoplasia. *Cochrane Database Syst Rev* 2015:CD005583.
- 5 Lee Y-C, Chiang T-H, Chou C-K, *et al*. Association between *Helicobacter pylori* eradication and gastric cancer incidence: a systematic review and meta-analysis. *Gastroenterology* 2016;150:1113–24.
- 6 Thung I, Aramin H, Vavinskaya V, *et al*. Review article: the global emergence of *Helicobacter pylori* antibiotic resistance. *Aliment Pharmacol Ther* 2016;43:514–33.
- 7 Graham DY, Fischbach L. *Helicobacter pylori* treatment in the era of increasing antibiotic resistance. *Gut* 2010;59:1143–53.
- 8 Savoldi A, Carrara E, Graham DY, *et al*. Prevalence of Antibiotic Resistance in *Helicobacter pylori*: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology* 2018;155:1372–82. e17.
- 9 Zamani M, Rahbar A, Shokri-Shirvani J. Resistance of *Helicobacter pylori* to furazolidone and levofloxacin: A viewpoint. *World J Gastroenterol* 2017;23:6920–2.
- 10 Grayson M, Lindsay M, Crowe S, *et al*. *Kucers' the use of antibiotics*. 7th ed. Boca Raton, Florida, America: CRC press, 2017: 3187–94.
- 11 Zheng ZT, Wang ZY, Chu YX, *et al*. Double-Blind short-term trial of furazolidone in peptic ulcer. *Lancet* 1985;1:1048–9.
- 12 Kwon DH, Lee M, Kim JJ, *et al*. Furazolidone- and nitrofurantoin-resistant *Helicobacter pylori*: prevalence and role of genes involved in metronidazole resistance. *Antimicrob Agents Chemother* 2001;45:306–8.

- 13 Su Z, Xu H, Zhang C, *et al.* Mutations in *Helicobacter pylori* porD and oorD genes may contribute to furazolidone resistance. *Croat Med J* 2006;47:410–5.
- 14 Graham DY, Lu H. Furazolidone in *Helicobacter pylori* therapy: misunderstood and often unfairly maligned drug told in a story of French bread. *Saudi J Gastroenterol* 2012;18:1–2.
- 15 Gajewska J, Szczypka M, Tudek B, *et al.* Studies on the effect of ascorbic acid and selenium on the genotoxicity of nitrofurans: nitrofurazone and furazolidone. *Mutat Res* 1990;232:191–7.
- 16 Tatsuta M, Iishi H, Baba M, *et al.* Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. *Int J Cancer* 1991;48:605–8.
- 17 Malekzadeh R, Ansari R, Vahedi H, *et al.* Furazolidone versus metronidazole in quadruple therapy for eradication of *Helicobacter pylori* in duodenal ulcer disease. *Aliment Pharmacol Ther* 2000;14:299–303.
- 18 Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.
- 19 ICH. Clinical safety data management: definitions and standards for Expedited reporting E2A 1994.
- 20 Zheng XL, Xu L. Comparison of 10-day and 14-day furazolidone-containing quadruple salvage therapies for *Helicobacter pylori* eradication. *Chinese Journal of New Drugs* 2013;22:2786–8.
- 21 Medical dictionary for regulatory activities. Available: <https://www.meddra.org> [Accessed 21 July 2018].
- 22 Higgins JPT, Altman DG, Gotzsche PC, *et al.* The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- 23 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
- 24 Egger M, Davey Smith G, Schneider M, *et al.* Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- 25 Begg CB, Mazumdar M. Operating characteristics of a RANK correlation test for publication bias. *Biometrics* 1994;50:1088–101.
- 26 Peters JL, Sutton AJ, Jones DR, *et al.* Performance of the TRIM and fill method in the presence of publication bias and between-study heterogeneity. *Stat Med* 2007;26:4544–62.
- 27 Brok J, Thorlund K, Gluud C, *et al.* Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. *J Clin Epidemiol* 2008;61:763–9.
- 28 Wetterslev J, Thorlund K, Brok J, *et al.* Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *J Clin Epidemiol* 2008;61:64–75.
- 29 Guyatt G, Oxman AD, Akl EA, *et al.* Grade guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–94.
- 30 Wang F, Wang X-yan, Jia Y, *et al.* [Five-day rabeprazole-based triple therapy for *Helicobacter pylori* infection]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2004;29:589–91.
- 31 Hosseini V, Mokhtare M, Gholami M, *et al.* A comparison between moderate- and high-dose furazolidone in triple regimens for *Helicobacter pylori* eradication in Iran. *Middle East J Dig Dis* 2014;6:195–202.
- 32 Graham DY, Lu H, Yamaoka Y. A report card to grade *Helicobacter pylori* therapy. *Helicobacter* 2007;12:275–8.
- 33 Zhuge L, Wang Y, Wu S, *et al.* Furazolidone treatment for *Helicobacter Pylori* infection: A systematic review and meta-analysis. *Helicobacter* 2018;23:e12468.
- 34 WHO. IARC monographs on the identification of carcinogenic hazards to humansWorld health organization. Available: <https://monographs.iarc.fr/list-of-classifications/> [Accessed 2020-1-20].
- 35 Mohammadi M, Attaran B, Malekzadeh R, *et al.* Furazolidone, an underutilized drug for H. pylori eradication: lessons from Iran. *Dig Dis Sci* 2017;62:1890–6.
- 36 Shenoy ES, Macy E, Rowe T, *et al.* Evaluation and management of penicillin allergy: a review. *JAMA* 2019;321:188–99.
- 37 Palm D, Magnus U, Grobecker H, *et al.* [Inhibition of monoamine oxidase by bacteriostatically active nitrofurans derivatives]. *Naunyn Schmiedeberg's Arch Exp Pathol Pharmacol* 1967;256:281–300.
- 38 Karamanakos PN. Furazolidone and serotonin syndrome: is there any association? *Clinics* 2008;63:553–4.
- 39 Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. *Scand J Gastroenterol Suppl* 1989;169:70–80.
- 40 Phillips KF, Hailey FJ. Furazolidone for treatment of diarrhoeal disease. *Trop Doct* 1987;17:89–91.
- 41 DuPont HL, Ericsson CD, Galindo E, *et al.* Furazolidone versus ampicillin in the treatment of traveler's diarrhea. *Antimicrob Agents Chemother* 1984;26:160–3.
- 42 Rabbani GH, Butler T, Shahrier M, *et al.* Efficacy of a single dose of furazolidone for treatment of cholera in children. *Antimicrob Agents Chemother* 1991;35:1864–7.
- 43 XJ Q, Shi BX, Jiang Y. Furazolidone-based firstline therapy for *Helicobacter pylori* infection in China: a meta-analysis. *World Chinese Journal of Digestology* 2016;24:4484–90.
- 44 Buzás GM, Józán J. Nitrofurantoin-based regimens for the eradication of *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 2007;22:1571–81.
- 45 Van Zwet AA, Thijs JC, van der Wouden EJ, *et al.* Low cure rate of *Helicobacter pylori* infection with omeprazole and furazolidone dual therapy for one week. *Aliment Pharmacol Ther* 1997;11:533–5.
- 46 Graham DY, Osato MS, Hoffman J, *et al.* Furazolidone combination therapies for *Helicobacter pylori* infection in the United States. *Aliment Pharmacol Ther* 2000;14:211–5.
- 47 Isakov V, Domareva I, Koudryavtseva L, *et al.* Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of *Helicobacter pylori* resistant to metronidazole. *Aliment Pharmacol Ther* 2002;16:1277–82.
- 48 Treiber G, Ammon S, Malfertheiner P, *et al.* Impact of furazolidone-based quadruple therapy for eradication of *Helicobacter pylori* after previous treatment failures. *Helicobacter* 2002;7:225–31.
- 49 Qasim A, Sebastian S, Thornton O, *et al.* Rifabutin- and furazolidone-based *Helicobacter pylori* eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. *Aliment Pharmacol Ther* 2005;21:91–6.
- 50 Tay CY, Windsor HM, Thirriot F, *et al.* *Helicobacter pylori* eradication in Western Australia using novel quadruple therapy combinations. *Aliment Pharmacol Ther* 2012;36:1076–83.
- 51 Liu WZ, Xiao SD, Shi Y, *et al.* Furazolidone-containing short-term triple therapies are effective in the treatment of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 1999;13:317–22.
- 52 Xiao SD, Liu WZ, Hu PJ, *et al.* High cure rate of *Helicobacter pylori* infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. *Aliment Pharmacol Ther* 1999;13:311–5.
- 53 Xiao SD, Liu WZ, Hu PJ, *et al.* A multicentre study on eradication of *Helicobacter pylori* using four 1-week triple therapies in China. *Aliment Pharmacol Ther* 2001;15:81–6.
- 54 Guo C-Y, Wu Y-B, Liu H-L, *et al.* Clinical evaluation of four one-week triple therapy regimens in eradicating *Helicobacter pylori* infection. *World J Gastroenterol* 2004;10:747–9.
- 55 Zhang Q, Hu C, Tan X, *et al.* Effectiveness of furazolidone-containing triple therapies with different courses of treatment for *Helicobacter pylori* infection. *Chinese Journal of Hospital Pharmacy* 2011;31:1799–802.
- 56 Zhang Q, Sha W, Wang Q. Therapeutic effect of clarithromycin-based triple therapy for *Helicobacter pylori* eradication. *Chinese Journal of Gastroenterology* 2012;17:480–2.
- 57 Chen W, Zhang G-Y, Zeng Y, *et al.* Furazolidone-based quadruple therapy as first-line treatment for *Helicobacter pylori* infection. *World Chinese Journal of Digestology* 2013;21:1366–71.
- 58 Li L, Yang W, Yang J, *et al.* Radical curative efficacy of quadruple therapy containing probiotics on persistent *Helicobacter pylori* infection: an efficacy observation. *Chinese Journal of Microecology* 2013;25:673–5.
- 59 Liang X, Xu X, Zheng Q, *et al.* Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant *Helicobacter pylori* infections in a prospective study. *Clin Gastroenterol Hepatol* 2013;11:802–7.
- 60 Zheng X-li, Xu L. [Efficacy of furazolidone-based quadruple therapy as rescue treatment for refractory *Helicobacter pylori* infection]. *Zhonghua Yi Xue Za Zhi* 2013;93:3496–9.
- 61 Ke Q, Lu S. The efficacy of golden Bifidobacterium combined with quadruple therapy on *Helicobacter pylori* infection. *Chinese Journal of Microecology* 2018;30:695–9.
- 62 Fakheri H, Malekzadeh R, Merat S, *et al.* Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of *Helicobacter pylori* in a population with a high metronidazole resistance rate. *Aliment Pharmacol Ther* 2001;15:411–6.
- 63 Yi D-M, Yang T-T, Chao S-H, *et al.* Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of *Helicobacter pylori* infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. *Medicine* 2019;98:e14408.
- 64 Daghighzadeh H, Emami MH, Karimi S, *et al.* One-Week versus two-week furazolidone-based quadruple therapy as the first-line treatment for *Helicobacter pylori* infection in Iran. *J Gastroenterol Hepatol* 2007;22:1399–403.

- 65 Cheng H, Hu F-L. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of *Helicobacter pylori*. *WJG* 2009;15:860–4.
- 66 Zhao R, Huo L. Efficacy of different terms and different drugs therapy for *Helicobacter pylori* eradication: a randomized controlled trial. *Chinese Journal of Practical Internal Medicine* 2012;32:796–9.
- 67 Xie Y, Zhu Y, Zhou H, et al. Furazolidone-based triple and quadruple eradication therapy for *Helicobacter pylori* infection. *World J Gastroenterol* 2014;20:11415–21.
- 68 Mokhtare M, Hosseini V, Tirgar Fakheri H, et al. Comparison of quadruple and triple furazolidone containing regimens on eradication of *Helicobacter pylori*. *Med J Islam Repub Iran* 2015;29:195.
- 69 Xu X, Zhang ZY, Sun WH. Effects of pantoprazole combined with furazolidone in *Helicobacter pylori* eradication therapy. *World Chinese Journal of Digestology* 2015;23:866–71.
- 70 Xie Y, Zhang Z, Hong J, et al. Furazolidone-containing triple and quadruple eradication therapy for initial treatment for *Helicobacter pylori* infection: a multicenter randomized controlled trial in China. *Helicobacter* 2018;23:e12496.
- 71 Coelho LGV, Martins GM, Passos MCF, et al. Once-Daily, low-cost, highly effective *Helicobacter pylori* treatment to family members of gastric cancer patients. *Aliment Pharmacol Ther* 2003;17:131–6.
- 72 Roghani HS, Massarrat S, Shirekhoda M, et al. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of *Helicobacter pylori*. *J Gastroenterol Hepatol* 2003;18:778–82.
- 73 Fakheri H, Merat S, Hosseini V, et al. Low-Dose furazolidone in triple and quadruple regimens for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2004;19:89–93.
- 74 Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *Gastroenterology* 2017;153:420–9.